First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) — Tangible Net Worth Ratio
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a Tangible Net Worth Ratio of 100.0% as of March 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($257.46 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore First Tracks Biotherapeutics, Inc. Ordin net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Tangible Net Worth Ratio (2023–2024)
This chart shows how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's Tangible Net Worth Ratio has changed across 2 annual periods from 2023 to 2024. As of March 2026, the ratio stands at 100.0%, reflecting net assets of $257.46 Million with intangible assets of $0.00 USD. For live market cap and overall valuation, see TRAXV market cap.
Annual Tangible Net Worth Ratio for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See financial agility of First Tracks Biotherapeutics, Inc. Ordin to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $391.60 Million | $0.00 | $441.89 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $409.85 Million | $0.00 | $444.11 Million | — |